Scholar Rock received FDA approval in mid-September, ahead of the decision date, and recorded $0.6 million of revenue. Operating expenses were $106.6 million, and the loss of $0.81 per share was narrower than expected.
Revenue was up about 77% on a core basis excluding maritime, and core revenue grew nearly 10% from the second quarter. It was the first quarter with no maritime revenue. Adjusted EBITDA was about negative $8.6 million, a 27% improvement from negative $11.8 million …
System revenue was $3.0 million, up 60% from a year ago, helped by partial recognition of the first U.S. Genesis X sale.Recurring Revenuewas up 6% from a year ago but down 4% from the second quarter.
Gross merchandise sales grew 7% to $2.6 billion, and revenue grew 7% to $502 million. Adjusted EBITDA rose 84% to $124 million, a 25% margin, the highest as a public company. Sales andMarketingcosts fell as a share of revenue.
Adjusted EBITDA was $10.5 million, a 13.8% margin. GrossMarginwas 46.3%, pressured by higher promotion, unfavorableFixed Costabsorption and higher freight and packaging costs tied to oil prices.
Third quarter revenue was about $26,000 versus about $36,000 a year ago, with a gross loss of about $47,000. Operating expenses were about $9.4 million versus $0.8 million a year ago, which included non-cash items. Funding came mainly fromEquityline ofCreditproceeds.
Staking held flat at roughly 9.4 million Gram at about a 16% gross annualized yield.Gross Profitrose to $4.0 million from $0.5 million.
Fourth quarter netRevenuewas $1.15 billion, up 5% from a year ago, and EBITDA reached $194 million. The EBITDAMarginexpanded 90 basis points, extending a 240 basis point gain over three years. Earnings per share rose 9%.
Bookings of $28.9 million topped revenue, liftingBacklogto $40.1 million. Gross margin improved to 26.5% from 3.2%, helped by higher selling prices, better mix,Volumeand inventory reserve adjustments.
Net income was $2.5 billion, including a $1.4 billion non-cash swap gain that flatters earnings per share. Full-year adjusted EBITDA guidance was raised to $10.0 billion to $10.3 billion from $8.7 billion to $9.1 billion, assuming a $21 to $22 per MMBtu liquefaction fee …